Application of estimand framework in ICH E9 (R1) to safety evaluation

被引:3
作者
Wang, Xuelong [1 ]
Yang, Ping [2 ]
Yuan, Shuai S. [3 ]
Wang, William W. B. [1 ]
机构
[1] Merck & Co Inc, BARDS, Rahway, NJ 07065 USA
[2] MSD China Holding Co Ltd, BARDS, Shanghai, Peoples R China
[3] GSK, Oncol Stat, Collegeville, PA USA
关键词
Safety; estimand framework; intercurrent events; oncology trial; pooled data analysis;
D O I
10.1080/10543406.2023.2189452
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Defining the right question of interest is important to a clinical study. ICH E9 (R1) introduces the framework of an estimand and its five attributes, which provide a basis for connecting different components of a study with its clinical questions. Most of the applications of the estimand framework focus on efficacy instead of safety assessment. In this paper, we expand the estimand framework into the safety evaluation and compare/contrast the similarity and differences between safety and efficacy estimand. Furthermore, we present and discuss applications of a safety estimand to oncology trials and pooled data analyses. At last, we also discuss the potential usage of safety estimand to handle the impacts of COVID-19 pandemic on safety assessment.
引用
收藏
页码:476 / 487
页数:12
相关论文
共 24 条
  • [1] Estimands in clinical trials - broadening the perspective
    Akach, Mouna
    Bretz, Frank
    Ruberg, Stephen
    [J]. STATISTICS IN MEDICINE, 2017, 36 (01) : 5 - 19
  • [2] Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials
    Akacha, Mouna
    Branson, Janice
    Bretz, Frank
    Dharan, Bharani
    Gallo, Paul
    Gathmann, Insa
    Hemmings, Robert
    Jones, Julie
    Xi, Dong
    Zuber, Emmanuel
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (04): : 419 - 426
  • [3] Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
    Chuang-Stein, Christy
    Beltangady, Mohan
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (01) : 3 - 7
  • [4] Reporting Adverse Drug Reactions in Product Labels
    Crowe, Brenda
    Chuang-Stein, Christy
    Lettis, Sally
    Brueckner, Andreas
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (04) : 455 - 463
  • [5] FDA (Food and Drug Administration), 2021, SPONS RESP SAF REP R
  • [6] FDA (Food and Drug Administration), 2005, PLANS
  • [7] FDA (Food and Drug Administration), 2005, PREM RISK ASS
  • [8] FDA (Food and Drug Administration), DEV US RISK MIN ACT
  • [9] FDA (Food and Drug Administration), 2021, MET RAND CONTR CLIN
  • [10] A proportional hazards model for the subdistribution of a competing risk
    Fine, JP
    Gray, RJ
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) : 496 - 509